CEO, UROVANT SCIENCES LTD.
WHY: Healthcare exec with specialty in urology. Taking over Irvine-based company as its principal medication that treats overactive bladder issues, vibegron, gets close to FDA approval and domestic sales can begin.
RECENT: Named to top role at Urovant in March, succeeding company’s first chief executive, Keith Katkin, who took company public in 2018. FDA nod for vibegron expected by year’s end.
NOTABLE:Â Oversaw the commercial launches of two of the most successful overactive bladder therapies in the U.S. as president of Americas Operations at Japanese giant Astellas Pharma Inc., where his unit generated $4B in annual revenue. Urovant Sciences Ltd. was acquired for $216M by Sumitovant Biopharm in March 2021.
